-
1
-
-
0032584086
-
Calcimimetics with potent and selective activity on parathyroid calcium receptor
-
Nemeth EF, Steffey ME, Hammerland LG, et al. Calcimimetics with potent and selective activity on parathyroid calcium receptor. Proc Natl Acad Sci USA. 1998 ; 95: 4040-4045.
-
(1998)
Proc Natl Acad Sci USA
, vol.95
, pp. 4040-4045
-
-
Nemeth, E.F.1
Steffey, M.E.2
Hammerland, L.G.3
-
2
-
-
0036904133
-
Calcimimetics: Therapeutic potential in hyperparathyroidism. Curr Opi
-
Cohen A., Silverberg SJ Calcimimetics: therapeutic potential in hyperparathyroidism. Curr Opi Pharmacol. 2002 ; 2: 734-739.
-
(2002)
Pharmacol.
, vol.2
, pp. 734-739
-
-
Cohen, A.1
Silverberg, S.J.2
-
3
-
-
0021326821
-
Parathyroid hormone and bone histology: Response to hypocalcemia in osteitis fibrosa
-
Voigts A., Felsenfeld AJ, Andress D., et al. Parathyroid hormone and bone histology: response to hypocalcemia in osteitis fibrosa. Kidney Int. 1987 ; 25: 445-452.
-
(1987)
Kidney Int.
, vol.25
, pp. 445-452
-
-
Voigts, A.1
Felsenfeld, A.J.2
Andress, D.3
-
4
-
-
0028788558
-
Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patient without aluminum toxicity
-
Wang M., Herez G., Sherrard DJ, et al. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patient without aluminum toxicity. Am J Kidney Dis. 1995 ; 26: 836-844.
-
(1995)
Am J Kidney Dis.
, vol.26
, pp. 836-844
-
-
Wang, M.1
Herez, G.2
Sherrard, D.J.3
-
5
-
-
0031920748
-
Association of serum phosphorous and calcium × phosphate product with mortality risk in chronic hemodialysis patients: A national study
-
Block GA, Hulbert-Sharon TE, Levin NW, et al. Association of serum phosphorous and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998 ; 31: 607-617.
-
(1998)
Am J Kidney Dis.
, vol.31
, pp. 607-617
-
-
Block, G.A.1
Hulbert-Sharon, T.E.2
Levin, N.W.3
-
6
-
-
0033920728
-
Increased risk of hip fracture among patients with end-stage renal disease
-
Alem AM, Sherrard DJ, Gillen DL, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000 ; 58: 396-399.
-
(2000)
Kidney Int.
, vol.58
, pp. 396-399
-
-
Alem, A.M.1
Sherrard, D.J.2
Gillen, D.L.3
-
7
-
-
0034084251
-
Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management
-
Block GA, Port FK Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis. 2000 ; 35: 1226-1237.
-
(2000)
Am J Kidney Dis.
, vol.35
, pp. 1226-1237
-
-
Block, G.A.1
Port, F.K.2
-
8
-
-
0034682247
-
Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis
-
Goodman WG, Goldin J., Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000 ; 342: 1478-1483.
-
(2000)
N Engl J Med.
, vol.342
, pp. 1478-1483
-
-
Goodman, W.G.1
Goldin, J.2
Kuizon, B.D.3
-
9
-
-
0037373070
-
The calcimimetic AMG073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease
-
Quarles LC, Sherrard DJ, Adler S., et al. The calcimimetic AMG073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol. 2003 ; 14: 575-583.
-
(2003)
J Am Soc Nephrol.
, vol.14
, pp. 575-583
-
-
Quarles, L.C.1
Sherrard, D.J.2
Adler, S.3
-
10
-
-
6444245707
-
The calcimimetic AMG 073 reduces parathyroid hormone and calcium × phosphorus in secondary hyperparathyroidism
-
Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium × phosphorus in secondary hyperparathyroidism. Kidney Int. 2003 ; 63: 248-254.
-
(2003)
Kidney Int.
, vol.63
, pp. 248-254
-
-
Lindberg, J.S.1
Moe, S.M.2
Goodman, W.G.3
-
11
-
-
11144353767
-
Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis
-
Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004 ; 350: 1516-1525.
-
(2004)
N Engl J Med.
, vol.350
, pp. 1516-1525
-
-
Block, G.A.1
Martin, K.J.2
De Francisco, A.L.3
-
12
-
-
2942511328
-
The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis
-
Ohashi N., Uematsu T., Nagashima S., et al. The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis. Br J Clin Pharmacol. 2004 ; 576: 726-734.
-
(2004)
Br J Clin Pharmacol.
, vol.576
, pp. 726-734
-
-
Ohashi, N.1
Uematsu, T.2
Nagashima, S.3
-
13
-
-
33846405177
-
In vitro metabolism and prediction of drug-drug interactions of calcimimetic agent cinacalcet HCl
-
Bajpai M., Esmay J., Chi V., Hayashi M., Poppe L., Kumar G. In vitro metabolism and prediction of drug-drug interactions of calcimimetic agent cinacalcet HCl. Drug Metab Rev. 2005 ; 37: 124.
-
(2005)
Drug Metab Rev.
, vol.37
, pp. 124
-
-
Bajpai, M.1
Esmay, J.2
Chi, V.3
Hayashi, M.4
Poppe, L.5
Kumar, G.6
-
14
-
-
0031723235
-
Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver
-
Ito K., Iwatsubo T., Kanamitsu S., Ueda K., Suzuki H., Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev. 1998 ; 50: 387-411.
-
(1998)
Pharmacol Rev.
, vol.50
, pp. 387-411
-
-
Ito, K.1
Iwatsubo, T.2
Kanamitsu, S.3
Ueda, K.4
Suzuki, H.5
Sugiyama, Y.6
-
15
-
-
1942455361
-
Database analyses for the prediction of in vivo drug-drug interactions from in vitro data
-
[erratum in Br J Clin Pharmacol. 58: 565-568 ].
-
Ito K., Brown HS, Houston JB Database analyses for the prediction of in vivo drug-drug interactions from in vitro data [erratum in Br J Clin Pharmacol. 58: 565-568 ]. Br J Clin Pharmacol. 2004 ; 57: 473-486.
-
(2004)
Br J Clin Pharmacol.
, vol.57
, pp. 473-486
-
-
Ito, K.1
Brown, H.S.2
Houston, J.B.3
-
16
-
-
28844476587
-
In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: Qualitative relationships, quantitative predictions, and the rank-order approach
-
Obach RS, Walsky RL, Venkatakrishnan K., Houston JB, Tremaine LM In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharamacol Ther. 2005 ; 78: 582-592.
-
(2005)
Clin Pharamacol Ther.
, vol.78
, pp. 582-592
-
-
Obach, R.S.1
Walsky, R.L.2
Venkatakrishnan, K.3
Houston, J.B.4
Tremaine, L.M.5
-
17
-
-
0031974059
-
In vitro approaches to predicting drug interactions in vivo
-
von Moltke LL, Greenblatt DJ, Schmider J., Wright CE, Harmatz JS, Shader RI In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol. 1998 ; 55: 113-122.
-
(1998)
Biochem Pharmacol.
, vol.55
, pp. 113-122
-
-
Von Moltke, L.L.1
Greenblatt, D.J.2
Schmider, J.3
Wright, C.E.4
Harmatz, J.S.5
Shader, R.I.6
-
18
-
-
0031971273
-
Omission of the deconjugation step in urine analysis and the unaltered outcome of CYP2D6 phenotyping with dextromethorphan
-
Basci NE, Bozkurt A., Kayaalp SO, Sayal A., Isimer A. Omission of the deconjugation step in urine analysis and the unaltered outcome of CYP2D6 phenotyping with dextromethorphan. Eur J Drug Metab Pharmacokinet. 1998 ; 23: 1-5.
-
(1998)
Eur J Drug Metab Pharmacokinet
, vol.23
, pp. 1-5
-
-
Basci, N.E.1
Bozkurt, A.2
Kayaalp, S.O.3
Sayal, A.4
Isimer, A.5
-
19
-
-
0022338958
-
Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation
-
Schmid B., Bircher J., Preisig R., Küpfer A. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Phamacol Ther. 1985 ; 38: 618-624.
-
(1985)
Clin Phamacol Ther
, vol.38
, pp. 618-624
-
-
Schmid, B.1
Bircher, J.2
Preisig, R.3
Küpfer, A.4
-
20
-
-
18844369894
-
Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm
-
Ito K., Hallifax D., Obach RS, Houston JB Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos. 2005 ; 33: 837-844.
-
(2005)
Drug Metab Dispos.
, vol.33
, pp. 837-844
-
-
Ito, K.1
Hallifax, D.2
Obach, R.S.3
Houston, J.B.4
-
21
-
-
0033994866
-
Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: Use of maximum unbound concentration of inhibitor at the inlet to the liver
-
Kanamitsu S., Ito K., Sugiyama Y. Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm Res. 2000 ; 17: 336-343.
-
(2000)
Pharm Res.
, vol.17
, pp. 336-343
-
-
Kanamitsu, S.1
Ito, K.2
Sugiyama, Y.3
-
22
-
-
0027167470
-
Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine
-
Brøsen K., Hansen JG, Nielsen KK, Sindrup SH, Gram LF Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol. 1993 ; 44: 349-355.
-
(1993)
Eur J Clin Pharmacol.
, vol.44
, pp. 349-355
-
-
Brøsen, K.1
Hansen, J.G.2
Nielsen, K.K.3
Sh, S.4
Gram, L.F.5
-
23
-
-
0032847231
-
Influence of CYP2D6 activity on the disposition and cardiovascular toxicity and the antidepressant agent venlafaxine in humans
-
Lessard É., Yessine MA, Hamelin BA, O'Hara G., LeBlanc J., Turgeon J. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity and the antidepressant agent venlafaxine in humans. Pharmacogenetics. 1999 ; 9: 435-443.
-
(1999)
Pharmacogenetics.
, vol.9
, pp. 435-443
-
-
Lessard, É.1
Ma, Y.2
Hamelin, B.A.3
O'Hara, G.4
Leblanc, J.5
Turgeon, J.6
-
24
-
-
0029853347
-
The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans
-
Capon DA, Bochner F., Kerry N., Mikus G., Danz C., Somogyi AA The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. Clin Pharmacol Ther. 1996 ; 60: 295-307.
-
(1996)
Clin Pharmacol Ther.
, vol.60
, pp. 295-307
-
-
Capon, D.A.1
Bochner, F.2
Kerry, N.3
Mikus, G.4
Danz, C.5
Somogyi, A.A.6
-
25
-
-
33846427366
-
Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl
-
Harris RZ, Salfi M., Posvar E., Hoelscher D., Padhi D. Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol. 2007 ; 63: 159-163.
-
(2007)
Eur J Clin Pharmacol.
, vol.63
, pp. 159-163
-
-
Harris, R.Z.1
Salfi, M.2
Posvar, E.3
Hoelscher, D.4
Padhi, D.5
-
26
-
-
9344234385
-
Pharmacokincetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily
-
Harris RZ, Padhi D., Marbury TC, Noveck RJ, Salfi M., Sullivan JT Pharmacokincetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. Am J Kidney Dis. 2004 ; 44: 1070-1076.
-
(2004)
Am J Kidney Dis.
, vol.44
, pp. 1070-1076
-
-
Harris, R.Z.1
Padhi, D.2
Marbury, T.C.3
Noveck, R.J.4
Salfi, M.5
Sullivan, J.T.6
-
27
-
-
19544367799
-
No effect of renal function or dialysis on pharmacokinetics of cinacalcet (Sensipar®/Mimpara®)
-
Padhi D., Harris RZ, Salfi M., Sullivan J. No effect of renal function or dialysis on pharmacokinetics of cinacalcet (Sensipar®/Mimpara®). Clin Pharmacokinet. 2005 ; 44: 509-516.
-
(2005)
Clin Pharmacokinet.
, vol.44
, pp. 509-516
-
-
Padhi, D.1
Harris, R.Z.2
Salfi, M.3
Sullivan, J.4
-
29
-
-
0034770465
-
Human drug metabolism and the cytochromes P450: Application and relevance of in vitro models
-
Venkatakrishnan K., von Moltke LL, Greenblatt DJ Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol. 2001 ; 41: 425-432.
-
(2001)
J Clin Pharmacol.
, vol.41
, pp. 425-432
-
-
Venkatakrishnan, K.1
Von Moltke, L.L.2
Greenblatt, D.J.3
-
30
-
-
0344938358
-
Inhibition and induction of cytochrome P450 (CYP) enzymes
-
Pelkonen O., Maenpaa J., Taabitsainen P., Rautio A., Raunio H. Inhibition and induction of cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 ; 28: 1203-1253.
-
(1998)
Xenobiotica
, vol.28
, pp. 1203-1253
-
-
Pelkonen, O.1
Maenpaa, J.2
Taabitsainen, P.3
Rautio, A.4
Raunio, H.5
-
31
-
-
29244447987
-
The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions
-
Obach RS, Walsky RL, Venkatakrishnan K., Gaman EA, Houston JB, Tremaine LM The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther. 2006 ; 316: 336-348.
-
(2006)
J Pharmacol Exp Ther.
, vol.316
, pp. 336-348
-
-
Obach, R.S.1
Walsky, R.L.2
Venkatakrishnan, K.3
Gaman, E.A.4
Houston, J.B.5
Tremaine, L.M.6
-
32
-
-
18844410849
-
Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants
-
Bachmann KA, Lewis JD Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants. Ann Pharmacother. 2005 ; 39: 1064-1072.
-
(2005)
Ann Pharmacother.
, vol.39
, pp. 1064-1072
-
-
Bachmann, K.A.1
Lewis, J.D.2
-
33
-
-
33644861762
-
Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug-drug interactions: Pitfalls, progress and promise
-
Bachmann KA Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug-drug interactions: pitfalls, progress and promise. Curr Drug Metab. 2006 ; 7: 1-14.
-
(2006)
Curr Drug Metab
, vol.7
, pp. 1-14
-
-
Bachmann, K.A.1
-
34
-
-
33644922913
-
Prediction of drug-drug interactions for AUCoral of high clearance drug from in vitro data: Utilization of a microtiter plate assay and a dispersion model
-
Yamamoto T., Suzuki A., Kohno Y., Nagata K., Yamazoe Y. Prediction of drug-drug interactions for AUCoral of high clearance drug from in vitro data: utilization of a microtiter plate assay and a dispersion model. Curr Drug Metab. 2006 ; 7: 135-146.
-
(2006)
Curr Drug Metab
, vol.7
, pp. 135-146
-
-
Yamamoto, T.1
Suzuki, A.2
Kohno, Y.3
Nagata, K.4
Yamazoe, Y.5
-
35
-
-
27444445468
-
Prediction of in vivo drug-drug interactions from in vitro data: Impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant
-
Brown HS, Ito K., Galetin A., Houston JB Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol. 2004 ; 60: 508-518.
-
(2004)
Br J Clin Pharmacol.
, vol.60
, pp. 508-518
-
-
Brown, H.S.1
Ito, K.2
Galetin, A.3
Houston, J.B.4
-
36
-
-
33645961595
-
The impact of in vitro binding on in vitro-in vivo extrapolations, projection of metabolic clearance and clinical drug-drug interactions
-
Grime K., Riley RJ The impact of in vitro binding on in vitro-in vivo extrapolations, projection of metabolic clearance and clinical drug-drug interactions. Curr Drug Metab. 2006 ; 7: 251-264.
-
(2006)
Curr Drug Metab
, vol.7
, pp. 251-264
-
-
Grime, K.1
Riley, R.J.2
-
37
-
-
0036891924
-
Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors
-
Tran TH, von Moltke L., Venkatakrishnan K., Granda BW, Gibbs MA, Obach RS Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. Drug Metab Dispos. 2002 ; 30: 1441-1445.
-
(2002)
Drug Metab Dispos.
, vol.30
, pp. 1441-1445
-
-
Th, T.1
Von Moltke, L.2
Venkatakrishnan, K.3
Granda, B.W.4
Ma, G.5
Obach, R.S.6
-
38
-
-
0031466149
-
Nonspecific binding to microsomes: Impact of scale-up of in vitro intrinsic clearance to hepatic clearance assessed through examination of warfarin, imipramine, and propranolol
-
Obach RS Nonspecific binding to microsomes: impact of scale-up of in vitro intrinsic clearance to hepatic clearance assessed through examination of warfarin, imipramine, and propranolol. Drug Metab Dispos. 1997 ; 25: 1359-1369.
-
(1997)
Drug Metab Dispos.
, vol.25
, pp. 1359-1369
-
-
Obach, R.S.1
-
39
-
-
0032941364
-
Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: Implication of concentrative uptake of inhibitors into liver
-
Yamano K., Yamamoto K., Kotaki H., Sawada Y., Iga T. Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver. Drug Met Dispos. 1999 ; 27: 395-402.
-
(1999)
Drug Met Dispos.
, vol.27
, pp. 395-402
-
-
Yamano, K.1
Yamamoto, K.2
Kotaki, H.3
Sawada, Y.4
Iga, T.5
-
40
-
-
0032755435
-
Kotaki H, et al. Correlation between in vivo and in vitro hepatic uptake of metabolic inhibitors of cytochrome-P450 in rats
-
Yamano K., Yamamoto K., Kotaki H, et al. Correlation between in vivo and in vitro hepatic uptake of metabolic inhibitors of cytochrome-P450 in rats. Drug Met Dispos. 1999 ; 27: 1224-1231.
-
(1999)
Drug Met Dispos.
, vol.27
, pp. 1224-1231
-
-
Yamano, K.1
Yamamoto, K.2
|